Drug intelligence / Profile preview

TMER-TIL

Development stage: Preclinical
Lead developer: Suzhou Lanma Medical Technology
Modality: Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

TMER-TIL is a genetically modified tumor-infiltrating lymphocyte (TIL) therapy being developed by Suzhou Lanma Medical Technology Co. Ltd. (Lanma Bio) for the treatment of solid tumors. The therapy utilizes the company's proprietary TMER (Tumor Microenvironment Remodeling) technology platform, which involves the genetic engineering of TILs to enhance their functionality and persistence within the immunosuppressive tumor microenvironment. By modifying the TILs, the platform aims to overcome common barriers to cell therapy in solid tumors, such as T-cell exhaustion and metabolic inhibition, thereby improving anti-tumor responses. As of early 2024, TMER-TIL is in the preclinical/early R&D stage of development.

Beyond the preview

Go deeper on TMER-TIL.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TMER-TIL.

Explore the full profile